Axomics

Axomics is a biotechnology company that develops computational tools and services for genomic research and precision biology. The company aims to accelerate discovery by providing scalable software for analyzing genomic and multi-omics data and by offering expert support for experimental design and data interpretation.

Founded in 2012 and based in San Francisco, Axomics was established by researchers Elena Park and Marcus Liu to address the growing need for integrated data analysis in genomics. The firm expanded through multiple funding rounds and established partnerships with academic laboratories and biopharmaceutical companies.

Axomics' primary products include the AxoCompute platform, a cloud-based suite for large-scale genome and transcriptome analysis, variant interpretation, and cross-omics integration; and AxoEdit, a design and evaluation toolkit to aid gene-editing workflows with built-in off-target and safety checks. The company also offers contract research and data-science consulting services.

In research and industry, Axomics' software is used for cancer genomics, rare disease studies, agricultural genomics, and translational science. Collaborations with universities and industry partners focus on building reproducible workflows, validating analytical methods, and accelerating regulatory-compliant data analysis.

As a privately held company, Axomics relies on venture funding and strategic partnerships. It maintains a global customer base and emphasizes open standards and interoperability with other bioinformatics tools. Its future priorities include expanding analytical capabilities, enhancing data governance, and supporting responsible innovation in genomics.